DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (NYSE Amex:AXK) announced the start of a comprehensive study that integrates its BACcel™ test methods using respiratory clinical specimens from ICU patients. Accelr8’s scientists had previously developed each of its test methods using cultured strains. Development then progressed to clinical specimens, focused on optimizing each individual step. The next stage of combining the steps begins with the new study. The study will test ICU respiratory specimens and compare results with those from standard culturing methods (the “gold standard” for testing). Study completion will constitute a major technical milestone toward commercialization.
